ZFHX3 and cardioembolic stroke: The population attributable risks in the METASTROKE discovery cohort were estimated as 5·8% for PITX2 and 7·0% for ZFHX3 in cardioembolic stroke, and 4·5% for HDAC9 and 7·2% for 9p21 in large-vessel disease.